

# Etica della terminalità nella SLA

*Andrea Calvo*




JAMA Neurology | Original Investigation

## Secular Trends of Amyotrophic Lateral Sclerosis in The Piemonte and Valle d'Aosta Register for ALS (PARALS)

Adriano Chiò, MD; Gabriele Mora, MD; Cristina Moglia, MD; Stefania Cammarosano, MD, PhD; Antonio Ilari, MD; Maurizio Grassano, MD; Fabrizio Pisano, MD; IRE Neuromuscular Unit, University of Turin, Italy


Figure 2. Incidence Rates by Age Groups and Sex



## Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study

Adriano Chiò,<sup>1,2</sup> Andrea Calvo,<sup>1</sup> Cristina Moglia,<sup>1</sup> Letizia Mazzini,<sup>3</sup> Gabriele Mora,<sup>4</sup> PARALS study group\*  
*J Neurol Neurosurg Psychiatry* 2011;**82**:740–746.

**Figure 3** Tracheostomy free survival, according to amyotrophic lateral sclerosis (ALS) phenotype. Yellow, PUMN; red, PLMN; light blue, pyramidal ALS; grey, flail arm; violet, classic ALS; green, flail leg; blue, bulbar; cyan, respiratory. Crosses are censored patients. PLMN, pure lower motor neuron phenotype; PUMN, pure upper motor neuron phenotype.



LMN UMN

Flail leg, 13.0%



Hemiplegic (rare)




## Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model



Henk-Jan Westeneng, Thomas P A Debray, Anne E Visser, Ruben P A van Eijk, James P K Rooney, Andrea Calvo, Sarah Martin, Christopher J McDermott, Alexander G Thompson, Susana Pinto, Xenia Kobeleva, Angela Rosenbohm, Beatrice Stubendorff, Helma Sommer, Bas M Middelkoop, Annelot M Dekker, Joke J F A van Vugt, Wouter van Rheenen, Alice Vajda, Mark Heverin, Mbombe Kazoka, Hannah Hollinger, Marta Gromicho, Sonja Körner, Thomas M Ringer, Annekatrin Rödiger, Anne Gunkel, Christopher E Shaw, Annelien L Bredenoord, Michael A van Es, Philippe Corcia, Philippe Couratier, Markus Weber, Julian Grosskreutz, Albert C Ludolph, Susanne Petri, Mamede de Carvalho, Philip Van Damme, Kevin Talbot, Martin R Turner, Pamela J Shaw, Ammar Al-Chalabi, Adriano Chiò, Orla Hardiman, Karel G M Moons, Jan H Veldink, Leonard H van den Berg

*Lancet Neurol* 2018  
Published Online  
March 26, 2017






## Prognostic communication in amyotrophic lateral sclerosis: findings from a Nationwide Italian survey

Cristina Moglia<sup>1,2</sup> · Francesca Palumbo<sup>1</sup> · Rossana Botto<sup>1,3</sup> · Barbara Iazzolino<sup>1</sup> · Nicola Ticozzi<sup>4,5</sup> · Andrea Calvo<sup>1,2</sup> · Paolo Leombruni<sup>1,3</sup> · MND Study Group of the Italian Society of Neurology

### Outcomes of Prognostic Communication in ALS patients



Frequency of Requests for Prognostic Discussion




Fig. 1 Graph showing the frequency of requests for prognostic discussion of physicians, patients and caregivers. Patients and caregivers request prognostic discussion more frequently than physicians (\*):  $p < 0.05$

Usefulness of the ENCALS prognostic model for Physicians, Patients, and Caregivers




Fig. 2 Graph depicting the perceived usefulness of the ENCALS prognostic model for physicians, patients, and caregivers. The model was considered more useful for physicians compared to patients (significant, \*:  $p < 0.05$ ), and caregivers





**Forum Risk Management**

**obiettivo** sanità & salute


**25-28 NOVEMBRE 2025**  
**AREZZO** FIERE E CONGRESSI



## Problematiche neurologiche di interesse palliativo nella SLA

- Dolore/disturbi sensitivi
- Nutrizione
- Comunicazione
- Motilità
- Problematiche associate alla motilità
- Correlati psicologici/psichiatrici
- Fine vita

## La SLA come modello di cure simultanee



Radunovic et al, Lancet Neurology 2007

## SLA: paradigma di scelte

- Comunicare la diagnosi e la prognosi
- Prescrivere terapie 'disease modifying' (riluzolo)
- La PEG/CVC
- La ventilazione non invasiva(NIV)/tracheostomia
- Controllo dei sintomi e qualità della vita
- Decisioni di fine vita, pianificazione condivisa delle cure (PCC)
- Il luogo di cura e di fine vita
- Le sperimentazioni cliniche
- Le terapie non convenzionali



**Grazie**